title: Interleukin-2-activated lymphocytes from brain tumor patients. A comparison of two preparations generated in vitro.
abstract: Two preparations of human recombinant interleukin-2 (rIL-2)-activated lymphocytes from patients harboring malignant brain tumors were characterized as autologous-stimulated lymphocytes (ASL) and lymphokine-activated killer (LAK) cells. ASL were generated from Ficoll-Paque-isolated, nonadherent, defibrinated peripheral blood lymphocytes (PBL) that were stimulated overnight with phytohemagglutinin (PHA) and cultured with rIL-2 (100 U/ml) for 10 days. LAK cells were produced by culturing all PBL in rIL-2 (500 U/ml) for 4 days. In 4-hour chromium release assays, LAK cells showed greater cytotoxicity than ASL against natural killer (NK)-sensitive and NK-resistant tumor cell lines; by 18 hours, the effectiveness of ASL equaled that of LAK cells. By electron microscopic study, PBL, LAK cells, and ASL showed differences. The helper/inducer to suppressor/cytotoxic ratio (T4+/T8+) of PBL, LAK cells, and ASL was 1.1:1, 1.0:1, and 0.4:1, respectively. ASL, when compared with PBL or LAK cells, have a significantly higher percentage of MO1+/DR+ and T8+/9.3+ subpopulations. ASL and LAK cells, used for the therapy of gliomas, are distinct.
authors: Department of Surgery, University of Colorado Health Sciences Center, Denver 80262.
authors: C A
authors: CA
authors: Kruse
authors: D H
authors: DH
authors: Mitchell
authors: K O
authors: KO
authors: Lillehei
authors: S D
authors: SD
authors: Johnson
authors: E L
authors: EL
authors: McCleary
authors: G E
authors: GE
authors: Moore
authors: S
authors: S
authors: Waldrop
authors: G W
authors: GW
authors: Mierau
mesh_terms: D000911:Antibodies, Monoclonal; D001932:Brain Neoplasms / Q000276:immunology*; D003602:Cytotoxicity, Immunologic; D005910:Glioma / Q000276:immunology*; D006801:Humans; D007376:Interleukin-2 / Q000494:pharmacology*; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology*; D008213:Lymphocyte Activation / Q000187:drug effects*; D009504:Neutrophils / Q000276:immunology / Q000648:ultrastructure; D010641:Phenotype; D011994:Recombinant Proteins / Q000494:pharmacology; D013601:T-Lymphocytes / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D007376:Interleukin-2; D011994:Recombinant Proteins